Complex Innovative Design
Decentralized Clinical Trials
European Medicines Agency
Hybrid Clinical Trials
In-Vitro Diagnostic Regulation
Outsourcing Clinical Trials
Real-World Evidence (RWE)
Research & Development
Research and Development
RWE Decision Alert
Alira Health Named One of the World’s Best Management Consulting Firms by Forbes
Alira Health is proud to announce it has been named by Forbes as one of the World’s Best Management Consulting Firms for 2023.
Alira Health enhances market access services via Centivis partnership
Alira Health, a global healthcare advisory and technology company, announced a strategic partnership with Centivis AG, a boutique market access consulting agency, specializing in digital(...)
Alira Health Expands North American Capabilities with Acquisition of Artisan Healthcare Consulting
The acquisition of Artisan strengthens and extends Alira Health’s Market Access and Management Consulting advisory practices in North America and globally.
Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
We acquired RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction(...)
Alira Health Strengthens Clinical Operations with the Acquisition of Sourcia
We acquired a full-service Contract Research Organization (CRO), Sourcia, that provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and(...)
Alira Health Secures an Additional $40M in Funding, Led by Creadev
We announced today the closing of an equity financing in which it raised gross proceeds of US$40 million. The financing was provided by key existing investors Creadev, an evergreen(...)
Alira Health Further Expands its Digital Healthcare Platform with the Acquisition of Patchai
We acquired Patchai, a digital health technology company headquartered in Italy. Patchai offers intelligent digital health solutions that engage and empower patients in clinical research(...)
Alira Health Acquires BEPATIENT, A Step Forward in Humanizing Healthcare
We acquired BEPATIENT, a European healthcare technology company. BEPATIENT offers ‘real life’ digital patient data capture solutions for large pharmaceutical manufacturers, medical(...)
Alira Health Announces its Role as Strategic Advisor to Naxicap
Alira Health is proud to announce its role as strategic advisor to Naxicap in the equity investment in Ceres Pharma Bv.
Alira Health Strengthens Growth Strategy with $35M Funding, led by Creadev
Alira Health strengthens its growth strategy with a $35M funding, led by Creadev.
2020 Year in Review
With 2021 in full swing, we want to take a moment to reflect on last year’s achievements and congratulate the entire Alira Health Team for their hard work and dedication to healthcare(...)
We Announce our role as Strategic Advisor to Mérieux Equity Partners and Mérieux Participations 3 for Entering the Capital of CTRS
We are pleased to announce our role as strategic advisor to Mérieux Equity Partners as they join the Series A financing round of Cell-Easy, through Mérieux’s newly established venture fund, OMX.
Welcome Daniela Sica, VP, Business Development, Pharma and Biotech
We are pleased to announce that Daniela Sica has joined the firm as Vice President, Business Development, Pharma and Biotech.
Latest from Alira Health
Technological Innovations in Diabetes Management Medical Devices
Discover the notable trends in the diabetes management devices market including glucose monitoring, insulin delivery and digital health.
Misconceptions About Patient-Centric Co-Design
Many people have misconceptions about patient-centric co-design, and these misconceptions are holding companies back.
Natural Language Processing for Analysis of Complex Diseases in the Hospital Setting (Lupus Case)
A hospital-specific NLP-powered platform can identify and characterize patients to provide pharma and biotech companies with fit-for-purpose RWD.
Pharma Develops e-Health Solution That Prioritizes Patients’ True Unmet Needs
A leading pharma company in the respiratory market sought support developing the right digital platform to expand their patient base and increase retention.
Bayesian Trial Design to Generate Evidence of the Safety and Efficacy of a Drug Regimen
A biotech company sought support in the design of their Phase II clinical trial to test the safety and efficacy of a novel inhibitor in combination with Pembrolizumab in patients with(...)
Leveraging a Virtual Site to Boost Diversity and Enrollment
The client’s study aimed to assess the sensitivity and specificity of a novel diagnostic test for colorectal cancer in a large population representative of the diversity in the US.
ACR Convergence 2023
We are pleased to announce that we will be joining ACR Convergence 2023, the world’s premier rheumatology event.
Spain Healthcare Innovation Summit
We will sponsor and speak at Spain Healthcare Innovation Summit, a premier event that brings together healthcare professionals from across Spain and beyond to discuss the latest developments(...)
Virtual Startup Demo Day
Join us and hear pitches from the leading startups in New England and beyond at the MassMedic Startup Virtual Demo Day.
How to Accelerate Lupus Solutions with RWD
Explore lupus solutions and real-world treatment impacts through a discussion on patient aspects and the role of technology in streamlining research efficiency.
How to Increase Patient Engagement in Your Clinical Trials
Join this webinar hosted by France Biotech to learn best practices and how to overcome challenges in engaging patients in your clinical trial.
Clinical Trials & Hospital Pilots
Kenny Carberry, VP, Business Development, Research & Clinical Development, joins the “Clinical Trials & Hospital Pilots” webinar as speaker.
SOHONOS, the First Drug for Fibrodysplasia Ossificans Progressiva, Receives US FDA Approval with Real-World Evidence as External Control
SOHONOS, the first drug for fibrodysplasia ossificans progressiva, receives US FDA approval with Real-World Evidence as external control
Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges
Our experts conducted a deep evaluation of IgG-like bsAbs including general advantages and disadvantages compared with MAbs and more.
Immunoglobulin Fc-Fusion Proteins
Our experts published a series of articles in BioProcess International reviewing the state of the art of Fc – fusion proteins, including their structure and molecular design, manufacturing(...)